Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
- Details
- Category: Impact Factor 5
- Hits: 3392
Clinical Cancer Research
1 juillet 2013
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J.
- Consulter la publication - IF > 5